Psoriatic Arthritis Treatment Market Size to Reach USD 23.2 Billion by 2033

Market Overview

The global psoriatic arthritis treatment market size was valued at USD 10.5 Billion in 2024. It is expected to grow to USD 23.2 Billion by 2033, exhibiting a CAGR of 8.71% during the forecast period from 2025 to 2033. Treatment options range from oral medications to biological therapies targeting immune system components with the goal of preventing disease progression, reducing pain, and preserving joint function. Physical therapy combined with these treatments helps strengthen muscles and enhance joint stability. 

Study Assumption Years

• Base Year: 2024
• Historical Years: 2019-2024
• Forecast Period: 2025-2033

Psoriatic Arthritis Treatment Market Key Takeaways

• Current Market Size: USD 10.5 Billion (2024)
• CAGR: 8.71% (2025-2033)
• Forecast Period: 2025-2033
• Psoriatic arthritis is an autoimmune disorder causing joint inflammation.
• Key players are developing treatments that prevent disease progression and protect joints while improving mobility.
• Psoriasis is a major risk factor that influences market growth.
• The disease most commonly affects adults aged 30 to 50, contributing to market growth.
• Rising awareness of early diagnosis and treatment benefits is boosting demand.

Request Free Sample Report: https://www.imarcgroup.com/psoriatic-arthritis-treatment-market/requestsample

Market Growth Factors

Psoriatic arthritis is an autoimmune inflammatory disease in the joints. Drug manufacturers develop agents for slowing disease progression and for protecting joints and mobility. Psoriasis is among the major factors affecting the market. It is most common among adults aged 30 to 50, and that factors into market growth patterns. People increasingly know about early diagnosis and treatment, so demand grows.Psoriasis disease can cause psoriatic arthritis thereafter. The market grows because psoriasis incidence increases given infectious agents, stress, obesity, skin lesions, alcohol intake, and vitamin deficiency.

Psoriasis relates to psoriatic arthritis toward a global demand for new treatments. Psoriatic arthritis is generally diagnosed in people around the ages of 30 and 50. Since the population of people aged 30-50 is expected to grow, this will be a growing market within the forecast period. Children with psoriatic arthritis can also have uveitis. Uveitis means the uvea has inflammation, and the uvea exists in the eye's middle layer. Uveitis seems more common among people with psoriatic arthritis and has caused concern among the parents of children with psoriatic arthritis.  Increased awareness that early diagnosis and treatment can halt or reverse pain and other damage to joints, along with rising disposable incomes and facilities, and a greater knowledge of new treatments relieving the worst symptoms are driving this.

Market Segmentation

IMARC Group segments the global psoriatic arthritis treatment market as follows:

• Drug Type:
• NSAIDs (Nonsteroidal Anti-Inflammatory drugs): Medications that reduce inflammation and pain.
• DMARDs (Disease-Modifying Anti-Rheumatic Drugs): Drugs modifying disease progression.
• Biologics: Therapies targeting specific components of the immune system.
• Others: Additional types of treatments not classified above.
• Type:
• Prescription: Medications requiring a doctor's prescription.
• OTC: Over-the-counter drugs available without prescription.
• Route of Administration:
• Injectable: Drugs administered via injections.
• Oral: Medications taken by mouth.
• Topical: Treatments applied directly on the skin.
• Distribution Channel:
• Hospital Pharmacies: Distribution through pharmacies located in hospitals.
• Retail Pharmacies: Dispensing via retail drug stores.
• Online Pharmacies: Internet-based pharmacy services.
• Region:
• North America: United States, Canada
• Asia-Pacific: China, Japan, India, South Korea, Australia, Indonesia, Others
• Europe: Germany, France, United Kingdom, Italy, Spain, Russia, Others
• Latin America: Brazil, Mexico, Others
• Middle East and Africa

Regional Insights

North America is the largest regional market for the psoriatic arthritis treatment. The market share or CAGR for this region has not been specified by the source. However, it has a large market share in other markets such as the United States and Canada.

Key Players

• AbbVie Inc.
• Amgen Inc.
• Amneal Pharmaceuticals LLC
• AstraZeneca plc
• Bristol-Myers Squibb Company
• Eisai Co. Ltd.
• Eli Lilly and Company
• Johnson & Johnson Service ltd.
• Novartis AG
• Pfizer Inc.
• Samsung Biologics
• UCB S.A.

Customization Note

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

Ask Our Expert & Browse Full Report with TOC & List of Figures: https://www.imarcgroup.com/request?type=report&id=4541&flag=E

About Us

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us

IMARC Group,

134 N 4th St. Brooklyn, NY 11249, USA,

Email: sales@imarcgroup.com,

Tel No: (D) +91 120 433 0800,

United States: +1-201971-6302